Mid-term outcomes of acute type B aortic dissection in Japan single center.
OBJECTIVE
To study mid-term outcomes in patients admitted to receive treatment for acute type B aortic dissection.


METHODS
The study group comprised 229 patients with acute type B aortic dissection treated between January 2000 and July 2010. 128 patients had a thrombosed false lumen, and 101 had a patent false lumen.


RESULTS
In the thrombosed group, 6 had rupture, 4 had malperfusion, and 118 had no complications. There were 5 early deaths (3.9%). In the patent group, 12 had rupture, 19 had malperfusion, and 70 had no complications. There were 6 early deaths (5.9%). Overall survival rates in the thrombosed group and the patent group were 94.7 ± 2.2% and 90.2 ± 3.2% at 1 year, and 84.3 ± 4.6% and 85.9 ± 4.3% at 5 years (p = 0.892), respectively. Aorta-related event-free rates were 85.6 ± 3.4% and 48.3 ± 5.5% at 1 year, and 76.0 ± 5.1% and 35.2 ± 7.2% at 5 years (p <0.001), respectively.


CONCLUSIONS
The incidences of rupture and malperfusion during the acute phase were higher in the patent group compared with the thrombosed group. At the late period, although the aorta-related event rate was higher in the patent group, the survival rate did not differ between two groups. Close follow-up and aggressive intervention strategy of the patent group may result comparable outcomes with the thrombosed group.
Yokohama City University Medical Center, Cardiovascular Center, Yokohama, Kanagawa, Japan.
Tomoyuki
T
Minami
Kiyotaka
K
Imoto
Keiji
K
Uchida
Shota
S
Yasuda
Norihisa
N
Karube
Shinichi
S
Suzuki
Munetaka
M
Masuda
D000368:Aged; D000784:Aortic Dissection / Q000150:complications / Q000628:therapy*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D017545:Aortic Aneurysm, Thoracic / Q000150:complications / Q000628:therapy*; D001019:Aortic Rupture / Q000209:etiology; D015331:Cohort Studies; D057510:Endovascular Procedures / Q000379:methods*; D005260:Female; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013927:Thrombosis; D016896:Treatment Outcome
D000959:Antihypertensive Agents